Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

SWOG S0777, a randomized phase III trial, compared bortezomib, lenalidomide and dexamethasone (VRd) with lenalidomide and dexamethasone (Rd). This updated analysis includes 460 patients evaluable for survival endpoints: 225 eligible and analyzable patients were randomized to Rd and 235 to VRd. The 6...

Descripción completa

Detalles Bibliográficos
Autores principales: Durie, Brian G. M., Hoering, Antje, Sexton, Rachael, Abidi, Muneer H., Epstein, Joshua, Rajkumar, S. Vincent, Dispenzieri, Angela, Kahanic, Stephen P., Thakuri, Mohan C., Reu, Frederic J., Reynolds, Christopher M., Orlowski, Robert Z., Barlogie, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214419/
https://www.ncbi.nlm.nih.gov/pubmed/32393732
http://dx.doi.org/10.1038/s41408-020-0311-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214419/
https://www.ncbi.nlm.nih.gov/pubmed/32393732
http://dx.doi.org/10.1038/s41408-020-0311-8

Ejemplares similares